A Cleveland Clinic first-in-human clinical trial has shown that a one-time infusion of a gene-editing therapy using CRISPR-Cas9 was effective and safe in reducing LDL ("bad") cholesterol and ...
NEW ORLEANS, LA—An investigational CRISPR-Cas9 gene-editing therapy that targets angiopoietin-like protein 3 (ANGPTL3), which has a role in regulating lipid metabolism, appears to safely lower levels ...
Data presented in a late-breaking presentation at the European Society of Cardiology (ESC) Congress 2026- -Phase 1a clinical ...
Gene editing reduced cholesterol by about 50% in an extremely small sample of patients over a year of follow-up, according to ...
The gene editing tool known as CRISPR-Cas9 is changing what's possible for treating a wide range of diseases caused by genetic mutations. But so far, attempts to use the technology to address ...
A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child with a rare genetic disorder. Unlike earlier ...
The CRISPR gene editing market is estimated at USD 4 billion in 2025 and is projected to reach USD 22 billion by 2035, expanding at a CAGR of 18.6% during the forecast period 2026–2035. The market is ...
Emerging gene-editing platforms are demonstrating that disease-causing mutations, aberrant gene expression, and even large-scale DNA insertions can be corrected without relying on error-prone DNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results